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lack of knowledge about exacerbation of bronchiectasis. Future efforts are required to better define
the biology of exacerbations. http://bit.ly/2XgjaHG
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ABSTRACT Bronchiectasis is a heterogeneous chronic disease. Heterogeneity characterises bronchiectasis
not only in the stable state but also during exacerbations, despite evidence on clinical and biological aspects
of bronchiectasis, exacerbations still remain poorly understood. Although the scientific community
recognises that bacterial infection is a cornerstone in the development of bronchiectasis, there is a lack of
data regarding other trigger factors for exacerbations. In addition, a huge amount of data suggest a primary
role of neutrophils in the stable state and exacerbation of bronchiectasis, but the inflammatory reaction
involves many other additional pathways. Cole’s vicious cycle hypothesis illustrates how airway dysfunction,
airway inflammation, infection and structural damage are linked. The introduction of the concept of a
“vicious vortex” stresses the complexity of the relationships between the components of the cycle. In this
model of disease, exacerbations work as a catalyst, accelerating the progression of disease. The roles of
microbiology and inflammation need to be considered as closely linked and will need to be investigated in
different ways to collect samples. Clinical and translational research is of paramount importance to achieve
a better comprehension of the pathophysiology of bronchiectasis, microbiology and inflammation both in
the stable state and during exacerbations.
Heterogeneity is the major challenge of bronchiectasis
Interest and awareness of bronchiectasis are increasing across both scientific and patient communities [1].
Bronchiectasis is recognised as a chronic respiratory disease characterised by an anatomic alteration
(abnormal and permanent dilatation of the bronchi) associated with specific clinical characteristics (cough,
sputum production and recurrent respiratory infections) that represents the final common pathway of
different disease processes [2, 3]. The identification of the underlying aetiology of bronchiectasis is one of the
main challenges, along with the heterogeneity, which also applies to other aspects of the disease [4]. From a
radiological point of view, the extent of bronchiectasis can range from focal to diffuse disease, and only
recently a dedicated score to evaluate radiological severity has been developed and validated in Europe [5].
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From a functional point of view, patients with bronchiectasis might show a variety of patterns ranging from
normal lung function to pathophysiological abnormalities, including obstructive, restrictive, isolated air
trapping or mixed patterns [6, 7]. From a clinical point of view, some patients might be paucisymptomatic.
In other patients, bronchiectasis may be detected unexpectedly through haemoptysis or pneumonia, whereas
others again may have daily symptoms of cough and sputum production with periodic exacerbations [8].
From a microbiological point of view, Pseudomonas aeruginosa and Haemophilus influenzae are the most
common bacteria detected in bronchiectatic airways but other pathogens including fungi, mycobacteria and
viruses can colonise and/or infect patients with bronchiectasis [9–11]. Detected microorganisms and the
balance between different microorganisms may vary among different continents and nations as pointed out
in a recent paper by CHANDRASEKARAN et al. [12]. Geographic variations in the airway microbiology of
bronchiectasis contribute to the observed differences in the epidemiology of the disease [12].
In light of the huge heterogeneity of the disease, international efforts have been made to identify clinical
phenotypes in patients with bronchiectasis [13, 14]. A clinical phenotype identifies a cluster of bronchiectasis
patients sharing similar clinical characteristics and biological pathways, and who might respond to the same
treatment [13]. Data from five European bronchiectasis registries identified four clinical phenotypes mainly
based on microbiological isolations and respiratory symptoms: Pseudomonas (16%), other chronic infection
(24%), daily sputum (33%) and dry bronchiectasis (27%) [13]. None of these phenotypes have been
replicated in independent cohorts. Furthermore, these studies did not consider the presence of specific
endotypes. An endotype is defined as a specific biological trait which characterises a group of patients with
bronchiectasis and that could also act as a target for a specific intervention [15]. Expanding work on
phenotypes and endotypes is of paramount importance to better understand the pathophysiologic
development of bronchiectasis and to select possible treatable traits of the disease [16]. Heterogeneity
characterises bronchiectasis not only in the stable state but also during exacerbations, although evidence on
clinical and biological aspects of bronchiectasis exacerbations still remain poorly understood.
Defining exacerbations in bronchiectasis: a clinical challenge
The identification of specific thresholds for the variation of each patient’s daily symptoms and the
minimum time required to start an exacerbation represent important challenges in the clinical
management of bronchiectasis. Finding the specific parameters necessary to define an exacerbation is
equally tricky. For this purpose, different definitions of exacerbations have been proposed over the past
decade. KAPUR et al. [17] found that changes in cough frequency or character, fever and increase in
purulent sputum are the most common features of bronchiectasis exacerbations. In the EMBRACE trial,
an exacerbation was defined as an increase or the new onset of more than one of the following pulmonary
symptoms: sputum volume, sputum purulence and dyspnoea [18]. The Spanish guidelines [19] and the
British Thoracic Society (BTS) guidelines [20] proposed different clinical definitions of exacerbations of
bronchiectasis and, despite the definitions seeming to be similar, there are some peculiarities that
differentiate them considerably (table 1). The updated version of the Spanish guidelines [21] also
introduced the concept of “very severe exacerbations” which includes haemodynamic instability, altered
mental status or the need for admission to an intensive or intermediate care unit.
In 2016, an international group of investigators developed a consensus definition of exacerbations for
clinical trials based on a systematic review of papers published over the past 15 years [22]. An exacerbation
was defined as a change in bronchiectasis treatment associated with deterioration in three or more of the
following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence;
breathlessness and/or exercise tolerance; fatigue and/or malaise; or haemoptysis. We note that this
definition still awaits validation in different settings [22, 23].
Clinical impact of bronchiectasis exacerbations
Exacerbations have a cornerstone role in bronchiectasis in terms of healthcare costs and negative impact
on patient prognosis [24, 25]. A large number of studies have shown that an increased frequency of
exacerbations results in increased airway and systemic inflammation and are associated with progressive
lung damage, worse quality of life, accelerated lung function decline and increased mortality [13, 25–27].
Reduction of the frequency of exacerbations and/or shortening time to the first exacerbation represent two
of the most reported outcomes in clinical trials in bronchiectasis [23, 28]; however, the pathobiology of
exacerbations is poorly understood and even their clinical manifestations are widely heterogeneous.
Exacerbations are generally considered as infectious events triggered by bacterial agents, and current
guidelines suggest antibiotic treatment to manage exacerbations [23, 28]. Despite these recommendations,
other potential causes of exacerbations in bronchiectasis have not thoroughly been investigated and
comorbidities could also play a relevant role, as is the case in other respiratory diseases [29, 30]. For
example, the association between high levels of environmental pollution and exacerbations suggests a role
for pollutants in increasing airway inflammation, suppressing host immunity and disturbing the biofilm,
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thus leading to an exacerbation [31]. Gastro-oesophageal reflux disease is one of the most important
comorbidities in bronchiectasis and has been associated with an increased number of exacerbations and
hospitalisations [30, 32, 33].
The frequent exacerbator phenotype
In recent years, some attempts have been made to identify the “frequent exacerbator” phenotype in
bronchiectasis to identify future targets for preventive therapies [34, 35]. To be useful in clinical practice the
phenotype needs to be stable over time and linked to relevant outcomes. CHALMERS et al. [34] demonstrated
a positive correlation between the median number of exacerbations in the previous year and the risk of
future exacerbations. These data were particularly strong in patients with more than three exacerbations per
year, reflecting on outcomes such as a worse quality of life measured with the St George’s Respiratory
Questionnaire and an increased rate of hospitalisation and mortality over 5 years [34]. Furthermore, these
data were supported by the findings of MARTINEZ-GARCIA et al. [35] in a South American cohort showing
higher mortality rates in patients with a history of two exacerbations or hospitalisation due to
bronchiectasis in the previous year.
Despite these data, there is no consensus concerning the minimum number of exacerbations that defines a
“frequent exacerbator patient” although the 2017 European Respiratory Society guidelines identified three or
more exacerbations as the threshold to start chronic antibiotic therapy to prevent future exacerbations [23].
Moreover, little is known regarding the causative factors that lead to an increased rate of exacerbations.
Chronic infection seems to be a relevant microbiological factor. Indeed, bronchiectasis patients with
P. aeruginosa chronic infection have worse outcomes, such as an increased risk of hospitalisation and an
TABLE 1 Definition of exacerbation according to different guidelines
Spanish guidelines 2008 [19] British guidelines 2010 [20] Consensus definition for
clinical research 2016 [22]
Spanish guidelines 2017 [21]
At least one of the following:
1. Changes in sputum
characteristics (increased
volume, thicker consistency,
greater purulence, or
haemoptysis)
2. Increased breathlessness
unrelated to other causes
Worsening of one or more of
the following:
1. Increasing sputum
volume or purulence
2. Worsening dyspnoea
3. Increased cough
4. Decline in lung function
5. Increased fatigue/
malaise
Deterioration in three or more
of the following key
symptoms for at least 48 h:
1. Cough
2. Sputum volume and/or
consistency
3. Sputum purulence
4. Breathlessness and/or
exercise tolerance
5. Fatigue and/or malaise
6. Haemoptysis
Increasing cough AND changes in
sputum characteristics (increased
volume, thicker consistency, greater
purulence)
May be accompanied by:
1. Worsening of cough
2. Fever
3. Asthenia
4. General discomfort
5. Anorexia
6. Weight loss
7. Pleuritic chest pain
8. Physical changes in the lungs
found during examination
9. Chest radiograph findings
suggestive of infection
10. Declining lung function
11. Elevated markers of systemic
inflammation
AND new appearance of one
or more of the following:
1. Fever
2. Pleurisy
3. Haemoptysis
4. Requirement of antibiotic
treatment
AND a clinician determines
that a change in
bronchiectasis treatment is
required
May be accompanied by:
1. Worsening dyspnoea
2. Fever
3. Asthenia
4. General discomfort
5. Anorexia
6. Weight loss
7. Chest pain
8. Haemoptysis
9. Changes in thoracic objective
exam
10. Requirement of changes in
bronchiectasis treatment
11. Declining lung function
Severe exacerbation: a severe exacerbation is one in which there is tachypnoea, acute respiratory failure, exacerbated chronic respiratory
failure, a significant decline in oxygen saturation or respiratory function, hypercapnia, fever >38°C, haemoptysis, haemodynamic instability,
and/or impaired cognitive function. Very severe exacerbation: haemodynamic instability, altered mental status or the need of admission to an
intensive or intermediate care unit.
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increased frequency of exacerbations [36–39]. Other chronic infections, as highlighted in a study by
CHALMERS et al. [34], are associated with an increased frequency of exacerbations, despite the lack of a clear
association with mortality. ARAÚJO et al. [40] showed that the combination of P. aeruginosa infection and a
higher number of exacerbations and hospitalisations in the previous year led to an increased risk of death in
bronchiectasis. However, the same study found that there was a small group of patients with P. aeruginosa
chronic infection without an increased rate of exacerbations. It is difficult to determine the reason why these
patients do not exacerbate frequently but the possibility that this group is at increased risk of death cannot
be excluded. From this perspective, research priorities include the need to better understand the role of P.
aeruginosa and identify the risk factors leading to disease progression, increased exacerbation rate and poor
outcomes in patients with bronchiectasis [41].
Exacerbations sustain the “vicious vortex” of bronchiectasis
Our understanding of bronchiectasis pathophysiology is limited, even though Cole’s “vicious cycle
hypothesis” is widely accepted as the paradigm of bronchiectasis development and progression [42]. The
hypothesis emphasises the role of four different components: impaired lung defences, inflammatory
response, airway damage and infection. The “entry point” which triggers the cycle is variable depending
on the underlying aetiology of bronchiectasis [43]. For instance, primary ciliary dyskinesia and
immunodeficiency impair host defences leading to an increased susceptibility to infection [44, 45].
Inflammatory bowel disease and rheumatoid arthritis stimulate an exaggerated lung inflammatory response
promoting lung structural damage [46, 47]. Aspiration causes direct tissue damage [48]. Moreover,
infections due to nontuberculous mycobacteria (NTM) encourage structural damage and lung
inflammation [11]. Some comorbidities act on the vicious cycle through several entry points. In chronic
rhinosinusitis, an inflammatory response begins in the upper airway and subsequently involves the lower
airway; chronic infection from the upper airway often extends to the lower airway through the migration
of secretions [49]. In addition, migration of secretions from the upper airway may also impair mucus
clearance in the lower airways [49].
Exacerbations are acute events that may accelerate the vicious cycle irrespective of the cause that is
responsible for the exacerbation, generating a hypothetical vicious vortex [50]. Targeting one aspect in
isolation, such as antibiotic use during an exacerbation to eliminate or reduce bacterial infection, only
blocks a single pathway of the disease and is likely to exert a modest impact on the overall progression of
the condition and on clinical outcomes. A multimodal approach would be optimal in order to better
target all the aspects of the disease that may be interdependent when the vortex is generated [16, 50].
Therefore, identifying the aetiologies of the exacerbation and finding biomarkers capable of predicting
future exacerbation risk and/or early detection of exacerbation development and response to therapy are of
paramount importance [41].
Microbiology during the stable state and exacerbations
Infection is one of the key points in both the stable state and during exacerbations of bronchiectasis.
Current guidelines suggest obtaining sputum cultures at least every year in stable bronchiectasis [23, 51].
Collecting lower airway specimens for microbiological examination is also recommended at the beginning
of an exacerbation to address targeted antibiotic therapy [23, 51].
Through traditional sputum cultures, the most common bacteria detected in patients with stable bronchiectasis
are P. aeruginosa and H. influenzae. Other bacteria isolated in sputum are NTM, Moraxella catarrhalis,
Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella spp. and Escherichia spp. [9, 10, 25]. The relative
frequencies of these bacteria in sputum samples vary among different populations (table 2). In European
studies, H. influenzae and P. aeruginosa are the most prevalent organisms isolated during the stable state as
shown by the EMBARC registry [52, 53]. In Northern Europe the most common bacteria isolated in
bronchiectasis patients is H. influenzae, while P. aeruginosa is the predominant bacteria in Southern
Europe [53]. In particular, the proportion of bronchiectasis patients with P. aeruginosa infection in Italy,
Greece and Turkey is >50% [53].
In Asia, as well as in Europe, data provided from different cohorts indicates that P. aeruginosa and
H. influenzae are the most common bacteria isolated with a low detection rate for NTM [54–56].
The US Bronchiectasis Research Registry provides different data compared with European and Asian
cohorts. The prevalent microorganisms detected in the airways of bronchiectasis patients are NTM with an
isolation rate of ∼50% [57]. The high rate of NTM isolation could be explained by the abundance of NTM
lung disease referral centres involved in the Bronchiectasis Research Registry [57–59]. Among NTM, the
most common species isolated are Mycobacterium avium complex, M. abscessus and M. chelonae [57]. In
over 1800 patients evaluated by the Bronchiectasis Research Registry, other bacteria isolated less frequently
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than NTM are P. aeruginosa (33%), S. aureus (12%), H. influenzae (8%) and Stenotrophomonas maltophilia
(5%) (table 2) [57].
Limited data suggest that during exacerbations, patients with bronchiectasis frequently isolate the same
bacterial species that they typically grow in sputum when stable [60, 61]. The species isolated during an
exacerbation could be the result of an increase in bacterial load of a pre-existing bacterial strain or may be
associated with acquisition of new strains as has been observed in COPD [62]. POLVERINO et al. [63]
considered two different groups of bronchiectasis patients during exacerbation. The first group included
patients with exacerbation leading to community-acquired pneumonia (CAP), whereas the second group
included exacerbated patients without CAP. Exacerbation was defined according to the Spanish guidelines
and the authors differentiated the presence of CAP in the context of bronchiectasis versus an exacerbation
without CAP when a new radiological infiltrate was detected on the chest radiograph by the attending
physician and confirmed by an external radiologist [19]. If the radiologist did not agree on the diagnosis
of pneumonia, the exacerbation was considered as a case of an exacerbation without CAP. The
microbiology samples show that S. pneumoniae was the most frequent bacteria isolated in the CAP group,
whereas P. aeruginosa was the most represented in the non-CAP group [63].
Among the infective causes of an exacerbation, bacteria play a leading role but, as stated in the 2019 BTS
guidelines, we lack data regarding the impact of viruses and fungi [51]. There are only a few studies
investigating the prevalence of respiratory viruses in adults and children with bronchiectasis during the
stable state and exacerbations [64–66]; however, the role of viruses is well defined in other respiratory
diseases as trigger factors for exacerbations, particularly in asthma and COPD [67–70]. Data from a
Chinese cohort show that virus prevalence is higher during exacerbations than in stable state
bronchiectasis [64]. The previously mentioned study by POLVERINO et al. [63] confirms a high prevalence of
respiratory viruses during exacerbations in Europe.
The role of fungi in bronchiectasis and particularly their role as a trigger factor for exacerbation is still unclear
and there is a great paucity of data on this argument [41]. Most microbiological studies in bronchiectasis
involve bacteria, while fungi are often considered as an incidental detection [12, 41]. Aspergillus spp. are the
most common fungi isolated in the sputum of patients with bronchiectasis. A. fumigatus can be both a
TABLE 2 Differences in microbiological prevalence among different continents
USA# Europe¶ Asia+
Haemophilus influenzae 8 57
Streptococcus pneumoniae 3 33
Staphylococcus aureus 12 23 1
Pseudomonas aeruginosa 33 49 20
Stenotrophomonas maltophilia 5 16 1
Klebsiella pneumoniae 2 14 4
Moraxella catarrhalis 1 24
Achromobacter 1 7
Alcaligenes 1
Serratia marcescens 2 10
Burkholderia species 0
Escherichia coli 13 1
Acinetobacter 6 1
Enterobacter cloacae 5 1
Proteus mirabilis 5
Mycobacterium tuberculosis 4
NTM 50 3 2
Mycobacterium avium complex 37
Mycobacterium abscessus/chelonae 10
Mycobacterium kansasii 1
Mycobacterium gordonae 3
Other mycobacterial species 3
Nocardia 1
Aspergillus species 19 10 6
Scedosporium apiospermum 3
Other fungal species 36
Candida species 11 6
Data are presented as %. NTM: nontuberculous mycobacteria. #: n=60; ¶: n=56; +: n=59.
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pathogen or an allergen but its role in provoking exacerbations is still unclear [71, 72]. Other fungi less
commonly isolated are Penicillium, Scedosporium and Fusarium spp. Interestingly, in a Spanish study,
antibiotic therapy was associated with a higher prevalence of fungal colonisation [73]. In two studies from the
UK, A. fumigatus colonisation or sensitisation was related to NTM infection and associated with a higher
mortality rate in bronchiectasis [74, 75].
In recent years, interest concerning NTM has grown considerably. The estimated prevalence of these
ubiquitous environmental organisms ranges from 0% to 60% in patients with bronchiectasis [57, 76–78]. It
is as yet unclear whether NTM actively cause bronchiectasis development or whether these agents colonise
and infect patients with a pre-existing predisposing condition (a chicken and egg situation). NTM lung
disease seems to be increasing in recent years, partly as a result of newer and more sensitive laboratory
detection methods [79]. Although there are a number of published guidelines regarding these pathogens,
more studies are needed to understand their role in exacerbations [79, 80].
From sputum culture to DNA analysis: the role of microbiome and mycobiome
DNA-sequencing technologies have changed our understanding of pulmonary microbiology in
bronchiectasis [81]. In recent decades, huge interest has grown around the role of the pulmonary
microbiome and its clinical implications. 16S rRNA gene sequencing is the most common method
targeting housekeeping genes to study bacterial phylogeny and taxonomy. The 16S rRNA gene contains
several regions that are present in almost all bacteria and it may be used to recognise and classify different
taxa and to estimate the richness and evenness of the pulmonary microbiota [81–83]. In the past, the lung
of healthy subjects was considered a sterile site because of negative results on standard sputum cultures.
Nowadays, through the use of DNA-sequencing technologies, an increasing body of evidence has shown
that viruses, bacteria and fungi coexist in the lungs of both healthy and ill people [84, 85]. Furthermore, it
is important to consider potential interactions that may increase virulence and pathogenicity as described
in nonrespiratory contexts [86]. The development of the microbiome depends on several factors such as
translocation from the upper airways, micro-aspiration and the efficacy of host defences [87, 88].
In bronchiectasis, several studies have shown that heterogeneity is the hallmark characteristic in
microbiome composition. Indeed, the heterogeneity in microbiome composition has implications on lung
function, severity of disease and inflammatory patterns [89, 90].
As previously observed in other respiratory diseases, a loss of bacterial diversity or the predominance of a
small group of taxa can be observed in bronchiectasis [91–95]. A loss of bacterial diversity is associated
with disease progression, worse lung function and an increased number of exacerbations [60, 89, 90].
The most commonly found genera are Haemophilus, Pseudomonas, Moraxella, Streptococcus, Veilonella,
Prevotella, Rothia and Klebsiella. There are differences between standard sputum culture and DNA
sequencing [90]. The presence of H. influenzae and M. catarrhalis seems to be under-recognised with
traditional techniques, while P. aeruginosa and S. aureus may be overestimated on standard culture, probably
due to their capacity to outgrow other bacteria [90]. Moreover, the prevalence of anaerobic bacteria varies
among sputum culture and DNA-sequencing techniques, and despite the role for anaerobic bacteria in the
onset of exacerbations being hypothesised, more studies are needed to clarify the possibility [60].
Changes in richness and evenness of the microbiome, measurable through different indexes, such as the
Shannon–Wiener index, are related to worsening lung function in bronchiectasis [96].
The relationship between antibiotic therapy and changes in the microbiome is still unclear. A secondary
analysis of the BLESS study (a randomised controlled trial analysing the effect of long-term administration
of erythromycin on exacerbation frequency) found that patients without Pseudomonas before the start of
treatment had changed their microbiome composition at the end of the trial with a great emergence of
Pseudomonas spp. [97]. These data have important clinical impact, in fact dominance of Pseudomonas
spp. is associated with more exacerbations and higher levels of inflammatory markers, such as
metalloproteinases [97, 98]. A recent study found that the microbiome is similar in the stable state, during
an exacerbation managed with antibiotics, and after full recovery from an exacerbation [90]. Indeed, the
use of antibiotics to treat an exacerbation only seems to exert a temporary effect on microbiome
composition. A few weeks after treatment it is no longer possible to highlight differences in microbiome
composition [60]. BYUN et al. [99] investigated differences in the microbiome during the stable state and
during exacerbations in patients with bronchiectasis but failed to find differences in microbial community
composition. This suggests that exacerbations may be triggered by a shift in microbiota behaviour rather
than a shift in its composition [99].
Standard bacterial studies on 16S rRNA sequencing have failed to clarify the role of fungi and viruses in
chronic respiratory diseases [100]. There are some data regarding mycobiome composition conducted on
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the internal transcribed spacer region of fungi suggesting that in respiratory disease there is a correlation
between reduction in fungal diversity and decline of lung function [101, 102]. In cystic fibrosis (CF),
mycobiome composition stability was reported after the completion of antifungal therapy during an
exacerbation [103]. Aspergillus is significantly more represented in the mycobiome of individuals with
bronchiectasis compared with healthy people and its presence correlates with exacerbations [104].
Little is known about the virome in bronchiectasis, and molecular methods to identify viruses present in
the respiratory tract without a priori knowledge of the organism are expensive. Moreover, the lack of a
universal viral molecular marker, such as 16S rRNA, or internal transcribed spacer region represents an
important challenge in the understanding of the virome [105]. A study conducted on patients with
respiratory tract infections showed that the most represented viruses are Paramyxoviruses followed by
Picornaviruses and Orthomyxoviruses, whereas in a small sample of patients with CF reticuloendotheliosis
virus, Epstein–Barr virus, Human Herpesvirus 6B and Human Herpesvirus 8 were found [106, 107]. More
studies are needed to assess the role of the virome in bronchiectasis.
Inflammatory markers and cytokines in stable bronchiectasis and during
exacerbations
Neutrophilic inflammation in the stable state and during exacerbations
Bronchiectasis is considered a chronic inflammatory disorder mainly driven by neutrophilic airway
inflammation [108]. The presence of an elevated number of neutrophils in the airway of patients with
bronchiectasis was found both in both the stable state and during exacerbations [109–111]. Moreover,
previous studies found that patients with bronchiectasis with chronic infection, in particular with
P. aeruginosa, are characterised by higher levels of neutrophils in sputum compared with patients with
bronchiectasis without chronic infection [27, 109, 110]. Indeed, bacterial colonisation promotes neutrophil
recruitment through upregulation of adhesion markers that are elevated in patients with bronchiectasis [27].
Despite the abundance of neutrophils in the airways of patients with bronchiectasis, the functional capacity
of neutrophils is blunted, generating the concept of a neutrophil paradox [112, 113]. A study conducted by
BEDI et al. [113] found that neutrophils show delayed apoptosis and increased activation in stable state
bronchiectasis, irrespective of disease severity. Interestingly, neutrophils isolated in sputum reveal defective
phagocytosis, favouring inefficient bacterial killing. Impaired bacterial killing capacity is also evident at the
onset of an exacerbation and persists beyond the clinical resolution of the exacerbation [113]. In the same
study, BEDI et al. [113] illustrated that patients with CAP also show defects in neutrophil killing capacity at
the onset of pneumonia, but neutrophil function recovers after a successful course of antibiotics. This study
exclusively involved patients with idiopathic bronchiectasis, and its results are in contrast with previously
published literature which did not report blood neutrophil defects in bronchiectasis [76, 114]. Further
studies are also needed in order to better understand whether the neutrophil paradox is suitable for patients
with known aetiologies of bronchiectasis.
Increased degranulation of neutrophil azurophilic granules releases proteases responsible for increased lung
damage [108]. One of the best studied proteases is neutrophil elastase (NE), a proteolytic serine-proteinase
[108]. NE is involved in several aspects, including ciliary beating rate inhibition, phagocytosis and bacterial
killing, extracellular matrix destruction, mucus gland hyperplasia induction, increased mucus production
in lung airways and direct airway damage [115–118]. Patients with stable bronchiectasis exhibit higher
sputum concentrations of NE than healthy subjects, even in the absence of bacterial colonisation [119].
Moreover, NE progressively increases with increasing bacterial load in the sputum, especially in patients
with P. aeruginosa chronic infection [27, 109, 120]. As a marker of airway inflammation, NE was also
found to increase during exacerbations and decrease after antibiotic treatment [27, 111, 120]. In a study
performed by CHALMERS et al. [27], antibiotic treatment administered for a bronchiectasis exacerbation
results in significant reduction of inflammatory markers, such as NE, tumour necrosis factor-α and
interleukin-8. Finally, previous evidence showed that higher levels of NE are associated with relevant
clinical outcomes in bronchiectasis, such as lung function decline, risk of future exacerbation and all-cause
mortality [111, 121]. NE in sputum is easy to measure and seems to be a promising biomarker to
categorise disease severity, predict exacerbations and define long-term clinical outcomes in bronchiectasis,
but future clinical trials are needed to validate cut-off values for NE activity and implement NE as a useful
biomarker in the clinical management of patients with bronchiectasis, both in the stable state and during
exacerbations [108].
Beyond neutrophilic inflammation in bronchiectasis
The presence of neutrophilic inflammation in bronchiectasis is widely described in both the stable state
and during exacerbations [109–111]. Data concerning the possible role of inflammatory pathways other
than neutrophilic during an exacerbation are lacking. Up to 35% of patients in the study by CHALMERS
et al. [111] had levels of NE activity <0.016 µg·mL−1 during the stable state and were considered as not
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having neutrophilic inflammation. Thus, it seems that inflammation in bronchiectasis is complex and
heterogeneous, and the variety in bronchiectasis aetiologies, as well as the lack of an animal model, limit
our understanding of the disease pathogenesis. Indeed, up to one-quarter of patients with bronchiectasis
have eosinophil-dominant airway inflammation [110, 122]. Macrophages in bronchiectasis airways could
be increased [123, 124]. Efferocytosis, the process by which apoptotic or necrotic cells are removed by
macrophages (the burying of dead cells), is impaired in bronchiectasis [125]. Failure to clear necrotic cells
results in increased inflammatory damage through unopposed granule product release and secondary
necrosis of apoptotic cells [126]. Future research should address the role of macrophages and eosinophils
not only during the stable state but also during an exacerbation of bronchiectasis.
Immune role of vitamin D
The main role of vitamin D in the regulation of calcium homeostasis and bone health has been known
since the beginning of the 20th century [127]. However, it was later discovered that the vitamin D receptor
is functional in tissues that are not involved in calcium metabolism [128, 129]. In the past decade, an
increasing number of publications focused on the extra skeletal effects of vitamin D, including the effect
on the human immune system and both chronic and infectious diseases [130–134]. Vitamin D reduces the
production of proinflammatory cytokines and regulates the secretion of antimicrobial peptides such as
cathelicidin (LL-37) which has potent antimicrobial activity against P. aeruginosa [130–132]. Furthermore,
a mouse model study showed that vitamin D deficiency directly caused alterations in the lung structure
and reduced lung function [133]. A recent study conducted by CHALMERS et al. [134] highlighted that 93%
of patients with bronchiectasis were either vitamin D deficient or insufficient, a percentage that was
significantly higher in comparison with the control group. Patients with vitamin D deficiency are more
commonly colonised, have lower forced expiratory volume in 1 s and a more rapid decline of lung
function over a 3-year follow-up period, have more frequent pulmonary exacerbations and have higher
sputum levels of inflammatory markers (myeloperoxidase, NE and interleukin-8). Given this evidence, it is
intriguing to speculate that vitamin D supplementation could be a reasonable therapeutic approach for
patients with bronchiectasis. Indeed, in patients with CF, vitamin D has been part of the standard
treatment for many decades [135]. The issue of the desirable target serum level (currently set at
>30 ng·mL−1) could be thorny if we consider administering vitamin D not just for preserving bone health
but with the intent of preventing lung diseases. Based on data currently available for patients with CF, the
dose needed in order to obtain a maximum immunomodulatory function is probably higher than the dose
required for optimal bone health [136]. A pilot study recently conducted in New Zealand found that
serum vitamin D levels in adults with bronchiectasis significantly increased after vitamin D oral
supplementation [137]. Designed randomised controlled trials are needed to demonstrate whether vitamin
D supplementation is associated with measurable disease outcomes, such as exacerbation rate and lung
function decline, to define which patients would benefit most from treatment, together with the serum
levels that have to be attained and the optimal doses.
Conclusions
Bronchiectasis is a very heterogeneous disease, both in the stable state and during exacerbations. Although
the scientific community recognises that exacerbations play a key role in the progression of the disease,
there is a lack of data regarding trigger factors for exacerbations. Currently, infections are considered as the
only cause of exacerbations with a leading role reserved for bacteria. We lack data regarding NTM, viruses
and fungi in bronchiectasis and their role as trigger factors for exacerbations is still unclear. The increasing
use of DNA-sequencing techniques in the study of the microbiota will provide a more complete perspective
on the role of microbiology, both in the stable state and during exacerbations of bronchiectasis. If our
knowledge on the microbiota is so far scant, even less is known about inflammatory markers and cytokines
in bronchiectasis. Data suggest a primary role for neutrophils, but the inflammatory reaction in
bronchiectasis involves many other additional factors. Cole’s vicious cycle hypothesis, revised by FLUME
et al. [50], illustrates how airway dysfunction, airway inflammation, infection and structural damage are
linked. The introduction of the concept of a vicious vortex stresses the complexity of the relationship
between the components of the cycle. In this model of disease, exacerbations work as a catalyst, accelerating
the progression of disease. The roles of microbiology and inflammation need to be considered as closely
linked and will need to be investigated by different ways to collect samples. Translational research is of
paramount importance to achieve reliable results. A better comprehension of the pathophysiology of
bronchiectasis, microbiology and inflammation, could allow the development of more characterised
phenotypes and endotypes in order to develop new clinical trials and find individualised treatment targets.
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